A run-in phase clinical study for intravesical administration of durvalumab in patients with high-risk, non-muscle-invasive bladder cancer (NMIBC)

Authors :: Kimon Tzannis
Charalampos Fragkoulis
N. Gavalas
K. Constantinides
E. Fragkiadis
Athanasios Papatsoris
Aristotle Bamias
Alexandros Pinitas
E. Giannopoulou
Konstantinos Stravodimos
Dionysios Mitropoulos
Charalampos Deliveliotis
Konstantinos Ntoumas
Source :: European Urology Open Science, Vol 19, Iss, Pp e1177-e1178 (2020)
Publication Year :: 2020
Publisher :: Elsevier, 2020.

Subjects :: medicine.medical_specialty
Durvalumab
Bladder cancer
business.industry
Urology
medicine.disease
lcsh:Diseases of the genitourinary system. Urology
lcsh:RC870-923
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
lcsh:RC254-282
Clinical study
Medicine
In patient
Non muscle invasive
business

Tools